Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis

病原菌快速鉴定及脓毒症诊断

• 批准号: 8522889
• 负责人: Ray Anthony Martino
• 金额: $ 99.49万
• 依托单位: ISENSE, LLC
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-15 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8522889
• 关键词: Academic Medical Centers; Accounting; Address; American; Antibiotic Therapy; Antibiotic susceptibility; Antibiotics; Blood; Blood Volume; Cause of Death; Clinic; Clinical; Collection; Culture Media; Detection; Device or Instrument Development; Diagnosis; Documentation; Drug Formulations; Goals; Grant; Growth; Hour; Human; Infection; Intensive Care Units; Laboratories; Libraries; Malignant neoplasm of lung; Malignant neoplasm of prostate; Measures; Methods; National Institute of Allergy and Infectious Disease; Organism; Patients; Performance; Phase; Predisposition; Process; Research; Sensitivity and Specificity; Sepsis; Site; Small Business Innovation Research Grant; Specimen; Speed; System; Systems Development; Technology; Testing; Time; United States; Variant; blind; commercialization; cost; cost effective; effective therapy; instrument; killings; malignant breast neoplasm; microorganism; pathogenic bacteria; prospective; public health relevance; software systems

DESCRIPTION (provided by applicant): Sepsis is the tenth-leading cause of death in the United States and the second-leading cause of death in the intensive care unit (ICU). Sepsis kills over 215,000 Americans each year - more than breast cancer, lung cancer, and prostate cancer combined. Rapid identification and determination of antibiotic susceptibility is critical fo effective treatment of infected patients. Phase I successfully demonstrated the iSense system's ability to discriminate bacterial species and strain 4-fold faster than legacy methods identify species alone. In Phase I iSense also successfully demonstrated the ability to determine strain-specific susceptibility to antibiotic therapy more than 1 day faster than conventional practice. Phase II aims address application to clinical human specimens along with development of instruments and media appropriate for commercial use. The ultimate goal of this research is to develop and commercially deploy an automated blood culture system that can diagnose sepsis, identify the species and strain of the infecting organism, and determine antibiotic susceptibility all in less than 24 hours from the lab's receipt of primary specimen.

描述（由申请人提供）：败血症是美国的第十个导致死亡原因，也是重症监护病房（ICU）的第二个领先原因。败血症每年杀死超过215,000名美国人 - 比乳腺癌，肺癌和前列腺癌多。快速鉴定和确定抗生素易感性是对感染患者的有效治疗。第一阶段成功证明了Isense系统能够区分细菌物种并比单独识别物种更快4倍的细菌物种和应变速度的能力。在第一阶段，ISENS还成功证明了比常规实践快1天以上的抗生素治疗易感性的能力。第二阶段的目的是针对临床人类标本的应用以及适合商业用途的仪器和媒体的开发。这项研究的最终目的是开发和商业部署一种自动化的血液培养系统，该系统可以诊断败血症，识别感染生物体的物种和菌株，并确定抗生素易感性在不到24小时的时间内从实验室收到主要标本后的不到24小时内。